Home › Funds › Maple Capital Management, Inc. › ABT

Maple Capital Management, Inc. position in ABT

ABBOTT LABORATORIES · Health Care

Maple Capital Management, Inc. reported holding 162,797 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$16.1M, representing 1.04% of its reported portfolio and ranking #27 among its reported holdings. Maple Capital Management, Inc. has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)162.80K sh
Reported value held$16.09M
Portfolio Weight1.04%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Maple Capital Management, Inc.'s ABT position evolved

Maple Capital Management, Inc. first disclosed a stake in ABT in Q3 2023 at 165,269 shares (US$16.0M). The position peaked in Q2 2025 at 172,197 shares, worth US$23.4M. Across 13 filings, Maple Capital Management, Inc. increased the stake 4 time(s), trimmed it 4 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 162,797 shares valued at US$16.1M — a reduction of -3,844 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 165.27K $16.01M New
Q4 2023 166.61K $18.34M Add
Q1 2024 167.65K $19.05M Add
Q2 2024 169.29K $17.59M Add
Q3 2024 169.74K $19.35M Hold
Q4 2024 169.37K $19.16M Hold
Q1 2025 169.96K $22.54M Hold
Q2 2025 172.20K $23.42M Add
Q3 2025 172.49K $23.10M Hold
Q4 2025 171.62K $21.50M Reduce
Q1 2026 168.65K $17.32M Reduce
Q2 2026 166.64K $15.12M Reduce
Q3 2026 162.80K $16.09M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 21 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has Maple Capital Management, Inc. held ABT?

Maple Capital Management, Inc. has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Maple Capital Management, Inc.'s current position in ABT?

As of Q3 2026, Maple Capital Management, Inc. holds 162.80K shares of ABT (ABBOTT LABORATORIES), valued at $16.09M, representing 1.04% of its reported portfolio and ranking #27.

Has Maple Capital Management, Inc. been buying or selling ABT?

In the latest 13F filing (Q3 2026), Maple Capital Management, Inc. reduced its position in ABT. The position peaked in Q2 2025 at 172.20K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 21 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.